Innate Pharma S.A.
IPHA · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$21,344 | -$24,707 | -$24,764 | -$9,288 |
| Dep. & Amort. | $707 | $852 | $1,142 | $1,446 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $1,554 | $2,238 | $1,706 | $2,855 |
| Change in WC | -$9,959 | $7,852 | $31,310 | -$13,047 |
| Other Non-Cash | -$2,122 | $3,833 | -$6,358 | -$3,059 |
| Operating Cash Flow | -$31,164 | -$9,932 | $3,036 | -$21,093 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$58 | -$108 | -$283 | -$42 |
| Net Acquisitions | $0 | $0 | $0 | $300 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $9,590 | $0 | $0 |
| Other Inv. Act. | $7,032 | -$1,214 | $1,215 | $20,619 |
| Investing Cash Flow | $6,974 | $8,268 | $932 | $20,877 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$4,456 | -$8,936 | -$4,420 | $0 |
| Stock Issued | $0 | -$186 | $186 | $94 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $14,932 | $7,441 | -$93 | -$814 |
| Financing Cash Flow | $10,476 | -$1,681 | -$4,327 | -$720 |
| Forex Effect | $1,022 | -$248 | -$257 | $129 |
| Net Chg. in Cash | $53,704 | -$3,594 | $69,990 | -$809 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $0 | $69,990 | $0 | $71,414 |
| End Cash | $53,704 | $66,396 | $69,990 | $70,605 |
| Free Cash Flow | -$31,222 | -$10,040 | $2,753 | -$21,135 |